How to Turn a $200M Biosimilar Into a $1B Franchise
The formulation play that created a 20-year monopoly
Most biosimilar companies are playing a losing game.
They spend 8-10 years and $100-200M developing a product that immediately enters a race to the bottom. They compete on 5% margin differences. Meanwhile, originators maintain their infusion center relationships and patient loyalty programs. The biosimilar manufacturers fight over scraps.
